Dr Terra Caudill

Satisfies Unmet Customer Need for Automated Performance Reports ABBOTT PARK, Ill., September 11, 2014 – Abbott has introduced worldwide a new, automated performance monitoring subscription, mView, for its widely used m2000 molecular diagnostics system. mView is designed to automate data analysis and help laboratories reduce the number of manually generated reports. A survey of molecular […]

September 8, 2014 – MIAMI–West Kendall Baptist Hospital in Miami has announced the purchase and installation of a highly advanced computed tomography (CT) scanner following a six-month evaluation at the hospital — the clinical trial of the equipment in the United States. With the convergence of whole-organ coverage, image quality, and speed found in GE […]

Wauwatosa, WI, September 3, 2014 — GE Healthcare (NYSE: GE) today announced the FDA approval of SenoClaire*, GE’s new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a […]

Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone Basel, 15 August 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin […]

First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer Basel, 06 August 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin […]

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 25, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Zydelig® (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients […]

82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 23, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the […]

Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib Basel, 4 July 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved alectinib for the treatment of people living with non-small cell lung cancer (NSCLC) […]

Acquisition of Phase I program offers a potential new approach for hormone receptor-positive breast cancer Basel, 2 July 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Genentech, a member of the Roche Group, has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in […]

Avastin is the first biologic medicine to receive a CHMP positive opinion for the most difficult to treat form of ovarian cancer The positive opinion is based on a pivotal phase III study showing that the addition of Avastin to chemotherapy reduced the risk of disease worsening or death by 62 percent Basel, 27 June […]